Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pabolizumab vs SOX as neoadjuvant therapy for Siewert II/III adenocarcinoma of the esophagogastric junction
ChiCTR2100046070Phase 2Recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in gastroesophageal adenocarcinoma (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Tumor regression grading. Started Jun 2021; status: recruiting.
02
Drugs
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100046070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046070.